![Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study](https://www.natap.org/2020/images/112420/112420-2/1124208.gif)
Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH) | Journal of Medicinal Chemistry
![Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study](https://www.natap.org/2020/images/112420/112420-2/1124201.gif)